isidoksiin

Isidoksa is a medication used to increase endogenous erythropoietin production. It is created by pharmaceutical company Jubilant Organosys of India. Isidoksa works by affecting the kidneys' ability to produce erythropoietin, which is a hormone responsible for stimulating the production of red blood cells in the bone marrow.

Isidoksa is used to treat anemia due to chronic kidney disease in patients with end-stage renal disease. It is administered orally in the form of tablets or capsules. The recommended dosage varies depending on the patient's creatinine clearance and hemoglobin levels.

Isidoksa's pharmacological properties are related to its influence on the production of erythropoietin. Studies have shown that it increases the number of red blood cells in patients with end-stage renal disease. However, its long-term effects on patients with chronic kidney disease are not well understood.

Side effects of Isidoksa include hypertension, headache, and nausea. Less common side effects include diarrhea, vomiting, and dizziness. It is contraindicated in patients with controlled hypertension or thromboembolic disease.

Isidoksa is synthesized from a chemical binding of an aromatic ring with various substituted amino groups. Research and development of Isidoksa began in the mid-20th century. Isidoksa's safety and efficacy were established in clinical trials before its approval for use in patients with chronic kidney disease.

No information available suggests that individuals with chronic kidney disease taking Isidoksa should change their diet significantly. Adequate nutrition helps the patient's existing health positively.